Citations

Clear

426 citation(s) found for "ST, Reza".

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis & Rheumatology | July 9, 2024 | Volume: 76 | Issue: 8 | Pages: 1182-1200

10.1002/art.42861 | PMID 38978310 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1051-1069

10.1002/acr.25348 | PMID 38973731 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce S., Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1070-1082

10.1002/acr.25347 | PMID 38973729 Get It

ObjectiveWe provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation.ResultsFifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high‐resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6‐minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs.ConclusionThis clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.
2023 American College of Rheumatology ( ACR )/American College of Chest Physicians ( CHEST ) Guideline for the Screening and Monitoring of Interstitial Lu
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce S., Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis & Rheumatology | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1201-1213

10.1002/art.42860 | PMID 38973714 Get It

Objective We provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease. Methods We developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation. Results Fifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high‐resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6‐minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.
Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging
Scalia, Isabel G. , Gheyath, Bashaer , Tamarappoo, Balaji , Moudgil, Rohit , Otton, James , Pereyra, Milagros , Narayanasamy, Hema, Herrmann, Joerg , Arsanjani, Reza , Larsen, Carolyn , Arsanjani, Reza , Pereyra, Milagros , Scalia, Isabel G

Mayo Clinic

Journal of Clinical Medicine | June 26, 2024 | Volume: 13 | Issue: 13 | Pages: 3714

10.3390/jcm13133714 | PMID 38999280 Get It

The long-term survivorship of patients diagnosed with cancer has improved due to accelerated detection and rapidly evolving cancer treatment strategies. As such, the evaluation and management of cancer therapy related complications has become increasingly important, including cardiovascular complications. These have been captured under the umbrella term “cardiotoxicity” and include left ventricular dysfunction and heart failure, acute coronary syndromes, valvular abnormalities, pericardial disease, arrhythmia, myocarditis, and vascular complications. These complications add to the burden of cardiovascular disease (CVD) or are risk factors patients with cancer treatment are presenting with. Of note, both pre- and newly developing CVD is of prognostic significance, not only from a cardiovascular perspective but also overall, potentially impacting the level of cancer therapy that is possible. Currently, there are varying recommendations and practices regarding CVD risk assessment and mitigating strategies throughout the cancer continuum. This article provides an overview on this topic, in particular, the role of cardiac imaging in the care of the patient with cancer. Furthermore, it summarizes the current evidence on the spectrum, prevention, and management of chemotherapy-related adverse cardiac effects.
Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention
Mahmoud, Ahmed , Awad, Kamal , Ali, Nima Baba , Pereyra, Milagros , Scalia, Isabel G. , Allam, Mohamed, Kamel, Moaz, Rmilah, Anan Abu , Chao, Chieh-Ju, Barry, Timothy, Lester, Steven J., Pollak, Peter , Sweeney, John P., Fortuin, David, Arsanjani, Reza , Mahmoud, Ahmed K , Allam, Mohamed N , Kamel, Moaz A, Alsidawi, Said , Pollak, Peter M, Alkhouli, Mohamad A, Lee, Richard W, Fortuin, David F, Arsanjani, Reza , Pereyra, Milagros , Scalia, Isabel G , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Allam, Mohamed N, Chao, Chieh‐Ju , Alsidawi, Said , Alkhouli, Mohamad , Lee, Kwan , Yang, Eric H. , Lee, Richard

Mayo Clinic

European Journal of Preventive Cardiology | June 20, 2024 | Volume: 31 | Issue: 15 | Pages: 1878-1887

10.1093/eurjpc/zwae212 | PMID 38916491 Get It

Abstract Aims Lipoprotein(a) [Lp(a)] has demonstrated its association with atherosclerosis and myocardial infarction. However, its role in the development of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) is not clearly established. The aim of this study is to investigate the association between Lp(a) and ISR. Methods and results A retrospective study of adult patients who underwent successful PCI between January 2006 and December 2017 at the three Mayo Clinic sites and had a preprocedural Lp(a) measurement was conducted. Patients were divided into two groups according to the serum Lp(a) concentration [high Lp(a) ≥ 50 mg/dL and low Lp(a) < 50 mg/dL]. Univariable and multivariable analyses were performed to compare risk of ISR between patients with high Lp(a) vs. those with low Lp(a). A total of 1209 patients were included, with mean age 65.9 ± 11.7 years and 71.8% were male. Median follow-up after baseline PCI was 8.8 [interquartile range (IQR) 7.4] years. Restenosis was observed in 162 (13.4%) patients. Median serum levels of Lp(a) were significantly higher in patients affected by ISR vs. non-affected cases: 27 (IQR 73.8) vs. 20 (IQR 57.5) mg/dL, P = 0.008. The rate of ISR was significantly higher among patients with high Lp(a) vs. patients with low Lp(a) values (17.0% vs. 11.6%, P = 0.010). High Lp(a) values were independently associated with ISR events (hazard ratio 1.67, 95% confidence interval 1.18–2.37, P = 0.004), and this association was more prominent after the first year following the PCI. Conclusion Lipoprotein(a) is an independent predictor for long-term ISR and should be considered in the evaluation of patients undergoing PCI.
High Lp(a) levels are a potential risk factor for aortic valve interventions in patients with bicuspid aortic valve
Farina, J M, Abbas, Moncef, Mahmoud, Ahmed K., Lester, S.C., Barry, Timothy, Marcotte, F, Pereyra, Milagros , Pereyra, Milagros , Arsanjani, Reza , Kamel, M A, Abbas, M T, Scalia, Isabel G. , Mahmoud, Ahmed , Ali, N Baba, Ayoub, C, Sell‐Dottin, Kristen , Alsidawi, Said , Lester, S, Majdalany, David S

Mayo Clinic

European Journal of Preventive Cardiology | June 14, 2024 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwae175.359 Get It

Abstract Background Bicuspid aortic valve (BAv) is associated with increased oxidative stress and inflammation, resulting in valve fibrosis, calcification, and ultimately early degenerative valve disease, often necessitating premature aortic valve intervention. In recent years, growing evidence has been published supporting the role of lipoprotein(a) [Lp(a)], an important carrier of oxidized phospholipids, in the development of aortic valve disease in the general population. However, the specific influence of Lp(a) levels in patients with BAv remains to be firmly established. Purpose To assess the role of Lp(a) levels in the development of aortic valve disease and the necessity for aortic valve interventions among individuals with BAv. Methods This retrospective multicenter study encompassed consecutive patients diagnosed with BAv from January 1997 to December 2022, all of whom had undergone serum Lp(a) measurement. This study evaluated the association between Lp(a) concentrations and the occurrence of aortic valve interventions. A cutoff point of ≥30 mg/dl for high Lp(a) levels was established. Binary logistic regression was utilized to calculate the odds ratio (OR) for an aortic intervention according to high versus low Lp(a) levels. Additionally, Kaplan Meier curves were employed to estimate the cumulative requirement for an aortic valve replacement based on Lp(a) concentrations. Results A total of 452 patients with BAv and a Lp(a) measurement were included in the study, with a mean age of 37.2 ±10.5 years at the time of BAv diagnosis, with 71.2% being male. Among these, 101 (22.3%) patients underwent an aortic valve replacement. In 72 cases (71.3%) aortic stenosis was the primary indication for intervention, while aortic regurgitation accounted for 29 cases (28.7%). The presence of elevated Lp(a) levels (≥30 mg/dl) demonstrated a significant association with the requirement for an aortic valve intervention (OR 2.2, 95%CI 1.4-3.6, p<0.001) in both the regression analysis and using the Kaplan-Meier estimator (Figure). High Lp(a) concentrations posed a risk factor for aortic valve replacements regardless of whether the primary indication for intervention was significant stenosis (OR 1.8, 95%CI 1.1-3.1, p=0.028) or regurgitation (OR 2.5, 95%CI 1.2-5.4, p=0.018). Conclusion Increased concentrations of Lp(a) may influence the clinical trajectory of patients with a BAv and may be a significant risk factor for aortic valve replacement, irrespective of the primary indication for intervention. Further investigations will be critical in unveiling the precise pathological mechanisms of Lp(a) in BAv. Confirming whether reducing Lp(a) levels could slow the progression of aortic disease in this demographic requires further exploration. Kaplan-Meier estimator.
Artificial Intelligence Assists in the Early Identification of Cardiac Amyloidosis
Kenyon, Courtney , Pereyra, Milagros , Rosenthal, Julie , Arsanjani, Reza , Kenyon, Courtney R , Pereyra, Milagros , Arsanjani, Reza

Mayo Clinic

Journal of Personalized Medicine | May 24, 2024 | Volume: 14 | Issue: 6 | Pages: 559

10.3390/jpm14060559 | PMID 38929780 Get It

A 69-year-old female presented with symptomatic atrial fibrillation. Cardiac amyloidosis was suspected due to an artificial intelligence clinical tool applied to the presenting electrocardiogram predicting a high probability for amyloidosis, and the subsequent unexpected finding of left atrial appendage thrombus reinforced this clinical suspicion. This facilitated an early diagnosis by the biopsy of AL cardiac amyloidosis and the prompt initiation of targeted therapy. This case highlights the utilization of an AI clinical tool and its impact on clinical care, particularly for the early detection of a rare and difficult to diagnose condition where early therapy is critical.
Activation of Aryl Hydrocarbon Receptor Inhibits Extracellular Matrix in Airway Smooth Muscle Cells
Reza, M.I., Kumar, Ajay , Balraj, Premanand , Britt, Rodney D. , Pabelick, Christina M. , Prakash, Y. S. , Sathish, Venkatachalem

Mayo Clinic

B79. AIRWAY SMOOTH MUSCLE IN ASTHMA | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4479-A4479

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4479 Get It

2-hydroxyestradiol (2HE) Attenuates the Airway Remodeling Via Activation of ERβ Receptor in Airway Smooth Muscle
Reza, M.I., Kumar, A., Ambhore, Nilesh Sudhakar , Pabelick, Christina M. , Prakash, Y. S. , Sathish, Venkatachalem

Mayo Clinic

B79. AIRWAY SMOOTH MUSCLE IN ASTHMA | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4474-A4474

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4474 Get It